![]() |
Abviva receives new patent grant notifications for MSA technology
Abviva, Inc., a biomedical company engaged in the development and commercialization of breast cancer related applications of Mammastatin, today provided further details about worldwide patent protection for its breast cancer risk assessment technology.
More... |
| All times are GMT -7. The time now is 03:01 PM. |
Powered by vBulletin® Version 3.8.7
Copyright ©2000 - 2026, vBulletin Solutions, Inc.
Copyright HER2 Support Group 2007 - 2021